RGEN vs SOLV: Repligen and Solventum compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Solventum is the larger company, worth $15.5B, about 1.6 times Repligen.
- Repligen grew revenue faster over the last year (+11.9% vs +2.2%).
- Solventum keeps more of each dollar of revenue as operating profit (25.0% vs 8.2%).
- On earnings, Solventum is the cheaper stock (10.9x vs 193.7x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | RGEN | SOLV |
|---|---|---|
| Market cap | $9.9B | $15.5B |
| Share price | $173.88 | $87.29 |
| Revenue (last fiscal year) | $738M | $8.3B |
| Free cash flow (last fiscal year) | $94M | -$10M |
| Revenue growth, last year | +11.9% | +2.2% |
| Revenue growth per year, last 5 fiscal years | +2.4% | +0.8% |
| Operating margin | 8.2% | 25.0% |
| Net margin | 5.3% | 17.3% |
| Return on equity | 2.0% | 29.9% |
| P/E (trailing) | 193.7x | 10.9x |
| Price / free cash flow | 105.9x | — |
| EV / EBITDA | 32.8x | 9.17x |
| FCF growth the price implies | 27.2% | — |
| Dividend yield | — | — |
| Debt / equity | 0.40x | 1.97x |
| Fundamental grade | D | C |
| Superinvestors holding it | 7 | 6 |
| Insider purchases, last 12 months | 0 | 1 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Repligen
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $671M | $52M | 24.9% |
| 2022 | $802M | $87M | 28.0% |
| 2023 | $632M | $78M | 7.5% |
| 2024 | $634M | $150M | -5.5% |
| 2025 | $738M | $94M | 7.5% |
Solventum
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2022 | $8.1B | $1.4B | 20.8% |
| 2023 | $8.2B | $1.6B | 20.6% |
| 2024 | $8.3B | $805M | 12.6% |
| 2025 | $8.3B | -$10M | 26.2% |
Where the revenue comes from
Repligen · by products, 2025
Product Revenue$738M100%
Royalty and other revenue$296,0000%
Solventum · by segments, 2025
MedSurg$4.8B60%
Health Information Systems$1.4B17%
Dental Solutions$1.3B17%
Purification and Filtration$497M6%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open RGEN in InvestinglyQuestions
Which is bigger, Repligen or Solventum?
Solventum (SOLV), at $15.5B against $9.9B.
Is RGEN or SOLV cheaper?
By trailing P/E, Solventum (10.9x) is cheaper than Repligen (193.7x). A lower multiple can also mean the market expects less growth.
Which grows faster, RGEN or SOLV?
Repligen: revenue grew +11.9% over the last year, against +2.2%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.